Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 1
2005 3
2006 1
2008 1
2009 6
2010 5
2011 8
2012 5
2013 9
2014 10
2015 8
2016 8
2017 11
2018 5
2019 12
2020 18
2021 18
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Multiple sclerosis and COVID-19.
Mares J, Hartung HP. Mares J, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-225. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020. PMID: 32686774 Free article. Review.
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: mares j. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e919. doi: 10.1212/NXI.0000000000000919. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33411674 Free PMC article. Review.
Drug Treatment of Clinically Isolated Syndrome.
Förster M, Graf J, Mares J, Aktas O, Hartung HP, Kremer D. Förster M, et al. Among authors: mares j. CNS Drugs. 2019 Jul;33(7):659-676. doi: 10.1007/s40263-019-00647-x. CNS Drugs. 2019. PMID: 31290079 Review.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: mares j. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e918. doi: 10.1212/NXI.0000000000000918. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33406479 Free PMC article. Review.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. O'Connor P, et al. Among authors: mares j. Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Neurology. 2016. PMID: 26865517 Free PMC article. Clinical Trial.
[Editorial].
Mareš J. Mareš J. Cesk Fysiol. 2015;64(1):1. Cesk Fysiol. 2015. PMID: 26738240 Slovak. No abstract available.
121 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page